Silo pharma announces positive results in subcutaneous delivery of its novel liposomes to treat arthritic patients

Englewood cliffs, n.j, july 12, 2022 (globe newswire) -- silo pharma, inc  . (otcqb: silo), a development-stage biopharmaceutical company today announces that its novel liposomes reached a positive endpoint in animal studies showing effectiveness and reduced toxicity using a subcutaneous delivery method.
SILO Ratings Summary
SILO Quant Ranking